BOJZ Mark Lourens (US),БОЙЗ Марк Лоуренс (US),BREhDLI Majkl (US),БРЭДЛИ Майкл (US),DELISL Robert Kirk (US),ДЕЛИСЛ Роберт Кирк (US),KhENNINGS D. Dejvid (US),ХЕННИНГС Д. Дейвид (US),KEhNNEDI Ehjpril L.,BOJZ MARK LOURENS,БОЙЗ Марк Лоуренс,BREHDLI MAJKL,БРЭДЛИ Майкл,DELISL ROBERT KIRK,ДЕЛИСЛ Роберт Кирк,KHENNINGS D. DEJVID,ХЕННИНГС Д. Дейвид,KEHNNEDI EHJPRIL L.,КЭННЕДИ Эйприл Л.,MARMSEHTER FREDRIK P.
申请号：
RU2012131129/04
公开号：
RU0002562977C2
申请日:
2010.12.20
申请国别(地区):
RU
年份:
2015
代理人:
摘要：
FIELD: medicine, pharmaceutics.SUBSTANCE: invention relates to novel formula I compounds and their pharmaceutically acceptable salts, which are cFMS inhibitors and are useful in treatment of bone diseases, cancer, autoimmune disorders, inflammatory diseases, cardio-vascular diseases and anaesthetics. Invention relates to versions of method of obtaining said compounds, pharmaceutical composition and method of treating bone diseases on their basis. In general formulaR1 represents hetAr1CH2-, hetAr2CH2-, (3-6Ccycloalkyl)-CH2-, benzyl, which is optionally substituted with (1-4C)alkoxy, or N-(1-3Calkyl)pyridinonyl-CH2-, which is optionally substituted with one or more substituents, independently selected from (1-6C)alkyl； hetAr1 is pyridyl, optionally substituted with one or more substituents, independently selected from (1-6C)alkyl, (1-4C)alkoxy, halogen, hetCyc1, hetCyc1-CH2-, amino(2-4C)alkoxy, [di(1-3Calkyl)amino](2-4C)alkoxy, dihydroxy(3-4C)alkoxy, hetCyc2O-, hetCyc2a(l-2C)alkoxy and OH； hetCyc1 is 6-membered heterocycle, which has 1-2 N atoms in ring and optionally substituted with NH2； hetCyc2 and hetCyc2a independently are 5-6-membered heterocycles, which have 1-2 N atoms in ring and are optionally substituted with one or more substituents, independently selected from (1-6C)alkyl, OH and halogen； hetAr2 is 5-membered heteroaryl ring, which has 2-3 heteroatoms in ring, independently selected from N, S and O, where, at least, one of said heteroatoms is N, where said ring is optionally substituted with one or more substituents, independently selected from (1-6C)alkyl, (2-4C)hydroxyalkyl, (3-4C)dihydroxyalkyl, (3-6Ccycloalkyl)CH2-, hetCyc3, hetCyc3a(1-2C)alkyl and benzyl, optionally substituted with (1-4C)alkoxy； hetCyc3 and hetCyc3a independently are 6-membered heterocyclic rings, which have 1-2 N atoms in ring and optionally substituted with halogen； R2 is (2-4C)alkyl, cyclopropyl, OMe, I or Br； R3 is H or Cl； R4 is H or CN； R5 is H, halogen, OH, hetAr3, hetAr4, he
